3-Hour infusion of single-agent paclitaxel for recurrent ovarian cancer

被引：13

作者：

Ishikawa H. ^{[1
]}

Nakanishi T. ^{[1
]}

Nawa A. ^{[1
]}

Suzuki Y. ^{[1
]}

Kuzuya K. ^{[1
]}

机构：

[1] Department of Gynecology, Aichi Cancer Center, Chikusa-ku, Nagoya 464-8681

来源：

International Journal of Clinical Oncology | 2001年 / 6卷 / 3期

关键词：

Ovarian cancer; Paclitaxel; Taxol;

D O I：

10.1007/PL00012094

中图分类号：

学科分类号：

摘要：

Background. The clinical response, survival, and toxicity of a 3-h infusion of single-agent paclitaxel (175 mg/m2) for Japanese patients with recurrent ovarian cancer were investigated. We also examined whether or not cancer antigen (CA) 125 would be suitable as an indicator of the effects of the paclitaxel on ovarian cancer. Methods. Twenty-one patients clinically diagnosed as having recurrent ovarian cancer met the entry criteria, agreed to participate in this study, and received the treatment. Results. One hundred and twenty-six courses were administered to the 21 patients. One patient achieved a complete response, and 5 a partial response; the overall response rate was 35.3%. Using CA125 criteria, 42.1% of patients achieved a response. The median progression-free interval was 4.4 months, and the median overall survival time was 14.5 months. While hematological toxicity was not severe, 3 patients experienced severe peripheral neuropathy, and 2 patients experienced grade 4 myalgia/arthralgia. Conclusion. The 3-h infusion of single-agent paclitaxel (175mg/m2) was an effective treatment for patients with recurrent ovarian cancer. CA125 was a useful indicator of the response to the treatment. While peripheral neuropathy and the myalgia/arthralgia were severe, 3-h infusion of single-agent paclitaxel offers a promising treatment for recurrent ovarian cancer.

引用

页码：128 / 131

页数：3

共 19 条

[1] Gore M.E., Levy V., Rustin G., Et al., Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: The UK and Eire experience, Br J Cancer, 72, pp. 1016-1019, (1995)
[2] Noda K., Ikeda M., Kudo R., Et al., Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intavenous infusion, Gan to Kagakuryoho (Jpn J Cancer Chemother), 23, pp. 317-325, (1996)
[3] Planner R.S., Allen D.G., Brand A.H., Et al., Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer, Aust NZ J Obstet Gynaecol, 36, pp. 168-170, (1996)
[4] Aravantinos G., Skarlos D.V., Kosmidis P., Et al., A phase II study of paclitaxel in platinum pretreated ovarian cancer, Eur J Cancer, 33, pp. 160-163, (1997)
[5] Tay S.K., Thilagam M.D., Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinumbased chemotherapy
[6] experience in an Asian population, Ann Acad Med Singapore, 27, pp. 645-649, (1998)
[7] Trope C., Hogberg T., Kaern J., Et al., Long-term results from a phase I study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience, Ann Oncol, 9, pp. 1301-1307, (1998)
[8] Oliverio G., Canuti D., Tononi A., Et al., Paclitaxel efficiency and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients, J Chemotherapy, 11, pp. 301-305, (1999)
[9] McGuire W.P., Hoskins W.J., Brady M.F., Et al., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 334, pp. 1-6, (1996)
[10] Piccart M.J., Bertelsen K., James K., Et al., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: 3-Year results, J Natl Cancer Inst, 92, pp. 699-708, (2000)

← 1 2 →